Resonance Health Ltd (ASX: RHT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Resonance Health Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$24.36 million
P/E Ratio
147.50
Dividend Yield
0.00%
Shares Outstanding
459.62 million
Earnings per share
0.000
Dividend per share
N/A
Year To Date Return
-1.67%
Earnings Yield
0.68%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Resonance Health Ltd (ASX: RHT)
Latest News
Small Cap Shares
Guess which 2 ASX small-cap shares just rocketed 50%+ on big news!
Healthcare Shares
Here's why the Resonance Health (ASX:RHT) share price is rocketing 36% today
Share Market News
Here's why the Resonance Health (ASX:RHT) share price rocketed
Share Market News
Resonance Health (ASX:RHT) announces its share price is in trading halt
Share Market News
The Resonance Health (ASX:RHT) share price has rocketed up 9% today. Here's why.
Share Market News
Why the Resonance Health (ASX:RHT) share price is shooting 39% higher today
Share Gainers
Why Afterpay, Creso Pharma, Healius, & Resonance Health shares are storming higher
Share Market News
Here's why these 3 ASX shares are trading higher today
Share Market News
Why the Resonance Health share price is rocketing 20% higher
⏸️ Investing
The WORST investing mistake I've made recently
RHT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Resonance Health Ltd
Resonance Health Ltd is a healthcare company specializing in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its product includes FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver, Cardiac T2, and HepaFat-Scan. It also has several AI-assisted SaMDs including FerriSmart, HepaFat-AI, and LiverSmart. The company's business segments are; Services which derives key revenue, Research and development, Corporate, Clinical Research Organization (CRO), and TrialsWest. Geographically, it generates maximum revenue from the Asia Pacific and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
RHT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Dec 2024 | $0.05 | $0.00 | 0.00% | 8,426 | $0.05 | $0.05 | $0.05 |
| 19 Dec 2024 | $0.05 | $-0.01 | -16.95% | 592,459 | $0.06 | $0.06 | $0.05 |
| 18 Dec 2024 | $0.06 | $0.00 | 0.00% | 674,605 | $0.06 | $0.06 | $0.06 |
| 17 Dec 2024 | $0.06 | $0.00 | 0.00% | 33,174 | $0.06 | $0.06 | $0.06 |
| 13 Dec 2024 | $0.06 | $0.00 | 0.00% | 32,392 | $0.06 | $0.06 | $0.06 |
| 12 Dec 2024 | $0.06 | $0.00 | 0.00% | 41,614 | $0.06 | $0.06 | $0.06 |
| 06 Dec 2024 | $0.07 | $0.00 | 0.00% | 376,389 | $0.07 | $0.07 | $0.07 |
| 05 Dec 2024 | $0.07 | $0.01 | 16.67% | 532,093 | $0.06 | $0.07 | $0.06 |
| 04 Dec 2024 | $0.06 | $0.00 | 0.00% | 249,916 | $0.06 | $0.06 | $0.06 |
| 03 Dec 2024 | $0.06 | $0.00 | 0.00% | 169,619 | $0.06 | $0.06 | $0.06 |
| 02 Dec 2024 | $0.06 | $0.00 | 0.00% | 191,251 | $0.06 | $0.06 | $0.06 |
| 29 Nov 2024 | $0.06 | $0.00 | 0.00% | 119,844 | $0.06 | $0.06 | $0.06 |
| 28 Nov 2024 | $0.06 | $0.00 | 0.00% | 45,273 | $0.06 | $0.06 | $0.06 |
| 27 Nov 2024 | $0.06 | $0.00 | 0.00% | 261,524 | $0.06 | $0.06 | $0.06 |
| 26 Nov 2024 | $0.06 | $0.00 | 0.00% | 251,304 | $0.06 | $0.06 | $0.06 |
| 25 Nov 2024 | $0.06 | $0.00 | 0.00% | 157,924 | $0.06 | $0.06 | $0.06 |
| 22 Nov 2024 | $0.06 | $0.01 | 18.87% | 436,309 | $0.05 | $0.06 | $0.05 |
| 21 Nov 2024 | $0.05 | $0.00 | 0.00% | 69,952 | $0.05 | $0.05 | $0.05 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 06 Nov 2024 | Mitchell Wells | Buy | 610,000 | $27,460 |
Conversion of securities.
|
| 06 Nov 2024 | Mitchell Wells | Exercise | 610,000 | $27,460 |
Conversion of securities. 610,000 PERFORMANCE RIGHTS
|
| 25 Jun 2024 | Travis Baroni | Buy | 85,000 | $5,015 |
On-market trade.
|
| 18 Jun 2024 | Travis Baroni | Buy | 3,320 | $199 |
On-market trade.
|
| 17 Jun 2024 | Travis Baroni | Buy | 81,680 | $4,900 |
On-market trade.
|
| 08 Apr 2024 | Simon Panton | Buy | 500,000 | $32,500 |
On-market trade.
|
| 20 Mar 2024 | Simon Panton | Buy | 500,000 | $23,000 |
On-market trade.
|
| 20 Mar 2024 | Simon Panton | Transfer | 73,300,000 | $4,617,900 |
Off-market transfer. Assuming off market transfer of shares
|
| 20 Mar 2024 | Simon Panton | Transfer | 73,300,000 | $4,617,900 |
Off-market transfer. Assuming off market transfer of shres
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Martin Peter Blake | Non-Executive DirectorNon-Executive Chairman | Oct 2007 |
Dr Blake is a Radiologist and Nuclear Physician who brings significant technical and industry experience to Resonance Health. He has been a Partner of Perth Radiological Clinic since 1997. He is a member of the Risk Committee.
|
| Mr Mitchell MacDonald Wells | Company SecretaryNon Executive Director | Jun 2023 |
Mr Wells is an experienced senior executive and a qualified lawyer with commercial and legal experience in Australia, the United States of America and the United Kingdom.
|
| Mr Simon Panton | Non-Executive Director | Oct 2009 |
Mr Panton brings skills in business and marketing having run his own successful business. He is a member of the Risk Committee.
|
| Dr Travis Baroni | Non-Executive Director | Nov 2016 |
Dr Baroni has broad experience across industrial research, commercialisation of technology, asset valuations and investment banking services. He has worked in investment banking, providing advisory services to equity capital market transactions, corporate research and valuations to clients. He is Chair of the Risk Committee.
|
| Mr Aaron Brinkworth | Non-Executive Director | Mar 2023 |
Mr Brinkworth had a 22-year career with Gilead Sciences, Inc. during which time the company grew from a small biotech-pharma company to a multi-billion-dollar global company with annual sales of over USD $27 billion. He held several commercial, licensing, and patient access roles at Gilead, including that of Executive Director - Global Patient Solutions, where he was responsible for commercial and access strategies for emerging markets.
|
| Mr Andrew Duncan Harrison | Chief Executive Officer | Jul 2023 |
-
|
| Andrew Duncan Harrison | Chief Executive Officer |
-
|
|
| Benjamin Carruthers | Chief Financial Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Southam Investments 2003 Pty Ltd <Warwickshire Investment A/C> | 74,300,000 | 16.63% |
| HSBC Custody Nominees (Australia) Limited | 49,401,078 | 11.05% |
| Mr Paul John Van Dyk | 9,250,031 | 2.07% |
| Mr Andrew Duncan Harrison & Mrs Katrina Ellen Harrison <Harrison Super Fund A/C> | 8,000,000 | 1.79% |
| Mr William Murray Thompson | 6,658,660 | 1.49% |
| Ms Jade Louise Thompson | 6,512,759 | 1.46% |
| Mr Harish Garg | 6,500,000 | 1.45% |
| Mr Bruce Alan Stevenson | 6,400,000 | 1.43% |
| Mr Paul Andrew Fitzmaurice & Mrs Tania Marie Fitzmaurice <Fitzmaurice Family S/F A/C> | 5,250,000 | 1.17% |
| Marcolongo Nominees Pty Ltd <Marcolongo Family A/C> | 5,186,200 | 1.16% |
| Mr Helmut Rocker | 5,000,000 | 1.12% |
| Mr Thomas Psarakis | 4,434,777 | 0.99% |
| Mr Evan George Cross & Mrs Donna Sharon Cross <Dec Superannuation Fund A/C> | 4,000,000 | 0.90% |
| Dr Martin Peter Blake | 3,798,590 | 0.85% |
| Dr Russell Kay Hancock | 3,782,704 | 0.85% |
| The University Of Western Australia | 3,478,750 | 0.78% |
| Morgan Stanley Australia Securities (Nominee) Pty Limited (No 1 Account) | 3,305,746 | 0.74% |
| Neweconomy Com Au Nominees Pty Limited (900 Account) | 3,197,656 | 0.72% |
| Cornucopia Assets Pty Ltd <Cornucopia Super Fund A/C> | 3,140,000 | 0.70% |
| Mr Robert Francis Panton | 2,800,000 | 0.63% |
